Literature DB >> 29406524

Formularies, costs, and quality of care: Limiting formularies is not harmful to patients.

William N Jones1.   

Abstract

Entities:  

Year:  2013        PMID： 29406524      PMCID： PMC5765943          DOI： 10.1212/CPJ.0b013e318283ff3e

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  8 in total

1.  Generic antiepileptic drugs and increased health care utilization: fact or myth?

Authors:  Frank M C Besag
Journal:  Neurology       Date:  2010-04-28       Impact factor: 9.910

2.  A safety assessment tool for formulary candidates.

Authors:  Amy M Pick; Firouzan Massoomi; William J Neff; Paula L Danekas; Anne M Stoysich
Journal:  Am J Health Syst Pharm       Date:  2006-07-01       Impact factor: 2.637

3.  Antiepileptic drugs and quality of life in the elderly: results from a randomized double-blind trial of carbamazepine and lamotrigine in patients with onset of epilepsy in old age.

Authors:  Erik Saetre; Michael Abdelnoor; Emilio Perucca; Erik Taubøll; Jouko Isojärvi; Leif Gjerstad
Journal:  Epilepsy Behav       Date:  2010-02-09       Impact factor: 2.937

4.  Generic antiepileptic drugs and associated medical resource utilization in the United States.

Authors:  D M Labiner; P E Paradis; R Manjunath; M S Duh; M-H Lafeuille; D Latrémouille-Viau; P Lefebvre; S L Helmers
Journal:  Neurology       Date:  2010-04-14       Impact factor: 9.910

Review 5.  Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.

Authors:  Aaron S Kesselheim; Margaret R Stedman; Ellen J Bubrick; Joshua J Gagne; Alexander S Misono; Joy L Lee; M Alan Brookhart; Jerry Avorn; William H Shrank
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

6.  Relationship of clinical and quality of life trajectories following the onset of seizures: findings from the UK MESS Study.

Authors:  Ann Jacoby; Steven Lane; Anthony Marson; Gus A Baker
Journal:  Epilepsia       Date:  2011-02-14       Impact factor: 5.864

7.  The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.

Authors:  Anthony G Marson; Asya M Al-Kharusi; Muna Alwaidh; Richard Appleton; Gus A Baker; David W Chadwick; Celia Cramp; Oliver C Cockerell; Paul N Cooper; Julie Doughty; Barbara Eaton; Carrol Gamble; Peter J Goulding; Stephen J L Howell; Adrian Hughes; Margaret Jackson; Ann Jacoby; Mark Kellett; Geoffrey R Lawson; John Paul Leach; Paola Nicolaides; Richard Roberts; Phil Shackley; Jing Shen; David F Smith; Philip E M Smith; Catrin Tudur Smith; Alessandra Vanoli; Paula R Williamson
Journal:  Lancet       Date:  2007-03-24       Impact factor: 79.321

8.  The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.

Authors:  Anthony G Marson; Asya M Al-Kharusi; Muna Alwaidh; Richard Appleton; Gus A Baker; David W Chadwick; Celia Cramp; Oliver C Cockerell; Paul N Cooper; Julie Doughty; Barbara Eaton; Carrol Gamble; Peter J Goulding; Stephen J L Howell; Adrian Hughes; Margaret Jackson; Ann Jacoby; Mark Kellett; Geoffrey R Lawson; John Paul Leach; Paola Nicolaides; Richard Roberts; Phil Shackley; Jing Shen; David F Smith; Philip E M Smith; Catrin Tudur Smith; Alessandra Vanoli; Paula R Williamson
Journal:  Lancet       Date:  2007-03-24       Impact factor: 79.321
  8 in total
  1 in total

1.  Formularies, costs, and quality of care.

Authors:  Nitin K Sethi
Journal:  Neurol Clin Pract       Date:  2013-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.